# Inectolizumab With Steroid Optimization in Newly Treated NMOSD

> **NCT07159893** · NA · NOT_YET_RECRUITING · sponsor: **First Affiliated Hospital of Wenzhou Medical University** · enrollment: 25 (estimated)

## Conditions studied

- Neuromyelitis Optica
- Autoimmune Diseases
- Demyelinating Autoimmune Diseases, CNS

## Interventions

- **DRUG:** Inebilizumab + Rapid Steroid Tapering group
- **DRUG:** Inebilizumab + Standard Steroid Tapering group

## Key facts

- **NCT ID:** NCT07159893
- **Lead sponsor:** First Affiliated Hospital of Wenzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09
- **Primary completion:** 2026-05
- **Final completion:** 2026-09
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07159893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07159893, "Inectolizumab With Steroid Optimization in Newly Treated NMOSD". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07159893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*